EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 732 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Duvelisib April 9, 2021 Mouse Study Points to Strategy for Preserving Bone During Chemotherapy February 25, 2020 Women and girls in science: We won’t stop pushing for progress February 11, 2023 Restaurant Opens Early For A 3-Year-Old Girl With Leukemia So She... February 21, 2020 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... New Research Looks for More Effective Breast Cancer Treatments for Black... “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain...
